Choroidal Neovascularization Market Report 2026

The choroidal neovascularization market size has grown strongly in recent years. It will grow from $4.18 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of age-related macular degeneration, rising diabetic eye disease cases, expansion of ophthalmology clinics, availability of anti-angiogenic drugs, improved retinal diagnostic capabilities.

The choroidal neovascularization market size is expected to see strong growth in the next few years. It will grow to $5.99 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing aging population, rising focus on early ophthalmic intervention, expansion of combination therapy approaches, growing investments in retinal disease research, increasing adoption of personalized treatment protocols. Major trends in the forecast period include increasing adoption of anti-vegf therapies, rising use of treat-and-extend regimens, growing demand for early cnv diagnosis, expansion of advanced retinal imaging techniques, enhanced focus on vision preservation therapies.

The rising prevalence of age-related macular degeneration (AMD) is expected to drive growth in the choroidal neovascularization (CNV) market. AMD is an eye condition that gradually damages the macula, causing central vision loss, primarily in older adults. The increasing prevalence of AMD is linked to factors such as an aging population, longer life expectancy, lifestyle changes, genetic predisposition, and greater environmental exposures. Choroidal neovascularization contributes to the development of wet AMD, where abnormal blood vessels grow beneath the retina, leading to vision deterioration. Advanced treatments, such as anti-VEGF therapy, are required to manage CNV, slow AMD progression, and preserve central vision. For instance, in 2025, according to the UHN Foundation, Canada-based official fundraising arm, AMD is the leading cause of significant, irreversible vision loss in individuals over 50, currently affecting over 200 million people worldwide, with projections reaching 288 million by 2040. Consequently, the increasing prevalence of AMD is driving the growth of the CNV market.

Major companies in the CNV market are focusing on innovative therapies such as photodynamic therapy (PDT) to provide eye care professionals with precise and efficient treatment options that improve outcomes. PDT is a medical treatment that uses a photosensitizing agent activated by light to target and destroy abnormal or diseased cells. For example, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced FDA approval for the ML6710i photodynamic laser. This therapy works in conjunction with Bausch + Lomb’s VISUDYNE treatment to target abnormal blood vessels in the eye caused by AMD, helping prevent disease progression and preserve vision.

In March 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, acquired the CIMERLI business from Coherus for $170 million. This acquisition expands Sandoz’s ophthalmic portfolio, enhancing its ability to offer innovative treatments for retinal diseases, including AMD. Coherus BioSciences, a US-based biopharmaceutical company, focuses on the research and development of therapies for conditions such as choroidal neovascularization.

Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated.

North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the choroidal neovascularization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the choroidal neovascularization market by increasing costs of imported biologic drugs, injectable delivery systems, diagnostic imaging equipment, and specialized ophthalmic instruments. Hospitals and ophthalmology clinics in North America and Europe are most affected due to dependence on imported anti-VEGF therapies and imaging devices, while Asia-Pacific faces cost pressures on pharmaceutical imports. These tariffs are raising treatment costs and affecting reimbursement dynamics. However, they are also encouraging regional drug manufacturing, localized formulation development, and increased investment in domestic ophthalmic therapeutics production.

The choroidal neovascularization market research report is one of a series of new reports that provides choroidal neovascularization market statistics, including choroidal neovascularization industry global market size, regional shares, competitors with a choroidal neovascularization market share, detailed choroidal neovascularization market segments, market trends and opportunities, and any further data you may need to thrive in the choroidal neovascularization industry. This choroidal neovascularization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Choroidal neovascularization (CNV) refers to the abnormal growth of blood vessels in the choroid layer of the eye, often extending into the retina. These fragile new vessels are prone to leaking fluid or blood, which can damage retinal tissues and result in vision distortion or loss.

The main treatment options for CNV include anti-angiogenic therapy, laser photocoagulation, photodynamic therapy, verteporfin sodium, ranibizumab, bevacizumab, aflibercept, and pegaptanib sodium. Anti-angiogenic therapy works by inhibiting the formation of new blood vessels (angiogenesis), helping to prevent abnormal vessel growth. These therapies are applied based on specific conditions such as age-related macular degeneration (AMD), diabetic macular edema (DME), central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), myopic macular degeneration (MMD), and other related disorders. Routes of administration include intravitreal, subconjunctival, periocular, and oral methods. These treatments are primarily delivered in hospitals, ophthalmology clinics, and ambulatory surgical centers.

The choroidal neovascularization market consists of revenues earned by entities by providing services such as diagnostic services, therapeutic services, and follow-up and monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The choroidal neovascularization market also includes sales of injections, therapy agents, and surgical & laser devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.